The IVD market will reach $78.44bn in 2020, a new study predicts

03 September 2018
Pharma

The analysis predicts the IVD market will continue to grow at a CAGR of 6.0% from 2015-2020, driven by the point-of-care submarket. In 2015, point-of care testing was the leading submarket primarily driven by blood glucose testing. This submarket will sustain strong growth throughout the coming decade
Visiongain predicts that the demand for IVDs will increase in line with the rise in both incidence and prevalence of chronic and infectious diseases. Health professionals will recognise that if these diseases can be diagnosed at the earliest stage possible, then damage to the individual can be minimised in addition to a reduction of later costs to healthcare systems. IVDs will be able to stem the economic and clinical costs of chronic and infectious disease.
Robert King, a pharmaceutical and healthcare industry analyst in visiongain, said:
“The rise in the global aging population will bear witness to an increasing incidence of age-related diseases, such as cardiovascular disease and cancer. This in turn has fuelled demand for advanced diagnostic testing equipment, capable of providing accurate clinical diagnoses, which allows for earlier medical intervention. In addition, technological innovations in this field have introduced increasingly miniaturised and automated devices into the marketplace, which has given rise to a new range of condition-specific tests. Furthermore, continued research and development in IVD has allowed for the discovery of new biomarkers, which has expanded the clinical application of IVD testing.
Globalisation and the market penetration of emerging countries, such as China and India, where there is a vast patient population pool, is providing huge opportunity in the IVD market. Owing to their rapidly growing economies, these countries have been ramping up healthcare spending, providing strong prospects for market players to direct their focus towards these geographical areas, rather than in developed countries. Also, molecular diagnostics have shown much promise in recent years, as pharmacogenomics and genetic testing have become an increasingly popular method of testing. These tests will become useful in elucidating possible genetic or hereditary links to a particular disease”
This report investigates commercial trends and revenues of the IVD market from 2016 to 2026, as well as including data from 2015. This report discusses sales potentials of:

• The IVD industry further divided 6 submarkets
o Point-of-care
o Clinical chemistry
o Immunochemistry
o Haematology
o Microbiology
o Genetic testing

• 11 leading individual national markets including:
o US
o Japan
o EU5 (Germany, France, UK, Italy and Spain)
o BRIC (Brazil, Russia, India and China)

• Leading IVD manufacturers including:
o Roche
o Danaher
o Abbott Laboratories
o Thermo Fisher Scientific
o Siemens
o Agilent

• Strengths, weaknesses, opportunities and threats of the global IVD market. Discussions include
o Innovation for IVD including robotics and automation
o Changes in legislation including updates by the US FDA on genetic screening and Japan’s PMD Act
o How changing patient demographics will favour IVD use

Recent News

Visiongain Publishes Big Data Analytics in Healthcare Market Report 2021-2031

Healthcare has never been more personalized and affordable to anyone. Digital consulting applications use artificial intelligence to provide medical advice based on customized medical history record reviews and general medical information derived from big data inferences.

13 May 2021

Read

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever